Skyrizi® Pre-fill Cartridge With Injector for Psoriasis, Psoriatic Arthritis, and Crohn’s

What Skyrizi® Is and How It Works

Skyrizi (risankizumab) is a biologic medicine that targets interleukin‑23 (IL‑23). By blocking the IL‑23 p19 subunit, it reduces inflammatory signaling that drives plaque psoriasis, psoriatic arthritis, and Crohn’s disease. The Skyrizi Pre-fill Cartridge w/ Injector is a subcutaneous maintenance presentation used for certain dosing regimens, while other forms include prefilled pens and syringes. If paying without insurance, many patients compare options to manage total cost over a full year of therapy.

YouDrugstore is a licensed Canadian pharmacy headquartered in Manitoba, and prescriptions are reviewed by licensed pharmacists before dispensing. We also work with licensed, vetted international partner pharmacies to keep authentic brand medications available across a broad selection at accessible pricing.

Indications vary by condition and dose. Adults with moderate to severe plaque psoriasis often receive 150 mg subcutaneously at week 0 and week 4, then every 12 weeks thereafter. Adults with psoriatic arthritis may use the same 150 mg schedule as monotherapy or with conventional DMARDs. In Crohn’s disease, induction is an intravenous infusion administered by a healthcare professional, followed by subcutaneous maintenance dosing that can use a prefill cartridge with an on‑body injector for the 360 mg option.

Administration is subcutaneous. The prefill cartridge loads into a single‑use on‑body injector that adheres to the skin and delivers the full dose automatically. Do not use the injector for intravenous induction doses. Patients should receive training on device setup and operation before first use.

Dosage and Usage

• Plaque psoriasis: 150 mg subcutaneously at week 0 and week 4, then every 12 weeks.
• Psoriatic arthritis: 150 mg subcutaneously at week 0 and week 4, then every 12 weeks, with or without methotrexate.
• Crohn’s disease: Induction by IV infusion at weeks 0, 4, and 8 under clinical supervision. Maintenance starting at week 12: 180 mg or 360 mg subcutaneously every 8 weeks. The 360 mg strength may be supplied as a prefill cartridge with an on‑body injector.
• Use the exact form and strength prescribed. Do not interchange IV induction and subcutaneous products.
• Missed dose: take the dose as soon as possible, then follow the new schedule. For detailed timing advice, contact the prescriber.
• Injection sites: abdomen or thigh are preferred; the back of the upper arm may be used if someone else administers the dose.
• On‑body injector steps (summary):

• Remove the carton from the refrigerator and let it reach room temperature on a flat surface. Do not heat externally.
• Wash hands. Check the carton, seal, cartridge label, and expiration date. Do not use if damaged or expired.
• Choose and clean the injection site with an alcohol swab; let it dry.
• Load the prefill cartridge into the injector as instructed by the device guide.
• Peel the adhesive backing, place the injector on the skin, and press firmly to secure.
• Start the injection per device instructions. Observe indicator lights and audible tones during delivery.
• When the device shows completion, remove it slowly. Confirm dose completion in the viewing window.
• Dispose of the used device and cartridge in a sharps container. Do not reuse.

• Storage and travel tips:

• Store Skyrizi refrigerated at 2–8°C (36–46°F) in the original carton. Do not freeze. Protect from light.
• Do not shake the cartridge or injector. Keep upright and handle gently.
• Before use, allow the device to reach room temperature on its own. Keep the cap on while warming.
• For travel, pack your medication in an insulated case with cold packs that do not touch the device directly. Keep between 2–8°C when possible.
• Do not expose to heat or direct sunlight. Do not use if the solution is cloudy, discolored, or contains particles.
• Keep all supplies together: alcohol swabs, cotton balls, a sharps container, and backup cold packs.

Benefits and Savings

Skyrizi can reduce plaques and itching in moderate to severe psoriasis and improve joint pain, swelling, and function in psoriatic arthritis. In Crohn’s disease, many patients see reductions in abdominal pain and stool frequency after induction, with maintenance helping sustain response. Dosing every 12 weeks for dermatologic conditions and every 8 weeks for Crohn’s maintenance supports long‑term adherence.

Ordering from a Canadian pharmacy often brings 60–80% savings versus typical U.S. prices. We support reorder reminders, and multi‑month supplies and select bulk promotions can reduce the per‑month cost. If purchasing without insurance, patients commonly compare the Skyrizi Pre-fill Cartridge w/ Injector to other forms to match budget and dosing needs. For limited‑time deals, see our Skyrizi Pre-fill coupon page.

Side Effects and Safety

• Upper respiratory tract infection (runny nose, sore throat)
• Headache
• Fatigue
• Injection site redness, pain, or swelling
• Tinea (fungal) infections
• Stomach pain or nausea

Serious reactions are uncommon but can include severe infections, hypersensitivity, and rare anaphylaxis. Screen for tuberculosis before starting therapy and avoid live vaccines during treatment. Discuss all current infections or recurrent infection history with the prescriber. When used with other immunosuppressants, infection risk can increase.

Onset Time

In plaque psoriasis, many patients notice improvement within 4–8 weeks, with clearer skin by week 16 as the schedule stabilizes. In psoriatic arthritis, joint symptoms may ease over 8–12 weeks, with gains in function as inflammation falls. In Crohn’s disease, symptom relief often follows IV induction, with maintenance benefits emerging by weeks 12–24.

Compare With Alternatives

Adalimumab is a tumor necrosis factor (TNF) inhibitor given by subcutaneous injection, typically every 1–2 weeks. It treats psoriasis, psoriatic arthritis, and Crohn’s disease. See Humira® for dosing differences and device options.

Ustekinumab targets IL‑12/23 and is used for psoriasis, psoriatic arthritis, and inflammatory bowel disease. Dosing begins with IV induction in some indications, then moves to subcutaneous maintenance. Compare with Stelara® Prefilled Syring to review schedules and strengths.

Etanercept is another TNF inhibitor given by subcutaneous injection and is used in psoriasis and psoriatic arthritis, but it is not indicated for Crohn’s disease. Patients who need IBD coverage often choose an IL or anti‑TNF agent with that indication.

Combination Therapy

• Psoriatic arthritis: Skyrizi may be used alone or with methotrexate or other conventional DMARDs.
• Plaque psoriasis: topical corticosteroids and moisturizers are often continued for comfort and flare control.
• Crohn’s disease: use with other potent biologics or JAK inhibitors is generally avoided due to additive immunosuppression.
• Vaccinations: complete needed inactivated vaccines before starting; avoid live vaccines during therapy.

Patient Suitability and Cost-Saving Tips

Skyrizi is intended for adults who meet diagnostic and severity criteria for psoriasis, psoriatic arthritis, or Crohn’s disease. It may not be appropriate for those with active serious infections, untreated latent tuberculosis, or a history of severe hypersensitivity to risankizumab or device components. Discuss pregnancy or breastfeeding plans with the prescriber to weigh benefits and risks.

Practical cost tips include using reorder reminders, aligning refills with travel plans, and comparing the 180 mg versus 360 mg maintenance options when applicable. Multi‑pack or bulk purchase promotions can lower per‑month costs. If you are paying with no insurance, consider coordinating a multi‑month supply to reduce shipping fees and plan budgets.

For storage and handling, plan ahead for trips, use insulated carriers, and keep a backup cold pack. Keep a sharps container ready at home. If a dose is delayed, contact the clinic for guidance on staying aligned with the prescribed schedule.

Authoritative Sources

Skyrizi Prescribing Information (AbbVie, U.S.)

Health Canada Drug Product Database: Risankizumab

FDA Label and Medication Guide: Skyrizi

Order Skyrizi® from YouDrugstore: add to cart, upload your prescription, and we ship with prompt, express, cold-chain handling.

This content is educational and does not replace advice from your healthcare professional.